Champions Oncology Stock Price and Value Analysis

Should you buy Champions Oncology stock? (NasdaqCM:CSBR). Let's see how it does in our automated value investing analysis system.

AdvantagesDisadvantagesNeutral
None.
  • This stock looks overpriced.
  • This company is less known than others.
  • This company is not making money.
  • This company has wild ups and downs.
  • This company pays no dividend.

Inside the CSBR Numbers

CSBR Price
(Champions Oncology stock price per share)
$8.62
[?] PE Ratio versus Sector 2885% higher than other Healthcare stocks
[?] PE Ratio versus Industry 946% higher than other Biotechnology stocks
[?] Free Cash Flow Jitter 61%

This stock has short interest! This means that people have shorted it.

Why does that matter? They've made a bet that price will decrease from where they bought it. Maybe there are financial problems, or maybe there's a value play.

As of the latest analysis, there are 174,078 shares shorted. With 6,550,740 shares available for purchase and an average trading volume over the past 10 trading days of 41,650, it would take at least 4.18 days for all of the short holders to cover their shorts.

Is Champions Oncology Stock on Sale?

Based on our analysis, we believe that you should not buy Champions Oncology right now. It might be a good stock to own—we just can't prove it with value analysis right now. Proceed with caution.

Should You Buy CSBR Stock?

Does Champions Oncology have a coherent story? Does it have a plan to continue to make money? Is it worth your time? Only you can decide where to go from here. Our investment guide helps you ask the right questions, including how to buy stocks. Use these research links for more information.